PP
MACK

PDT Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

PDT Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-36,859
Closed -$142K – 575
2018
Q2 		$142K Sell
36,859
-30,631
-45% -$203K 0.01% 491
2018
Q1 		$427K Sell
67,490
-6,233
-8% -$51.6K 0.01% 451
2017
Q4 		$595K Buy
+73,723
New +$687K 0.02% 412
2014
Q4 		– Sell
-16,199
Closed -$1.12M – 1288
2014
Q3 		$1.12M Buy
16,199
+11,344
+234% +$606K 0.03% 598
2014
Q2 		$278K Buy
+4,855
New +$247K 0.01% 1221

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

PDT Partners's MACK Position: Q3 2018 in Review

PDT Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2018, closing a stake of 36,859 shares — an estimated $142K sold.

PDT Partners first reported a position in MACK in Q2 2014 and held it in 5 quarters. The position peaked at $1.12M in Q3 2014. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

  • PDT Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • PDT Partners sold 36,859 Merrimack Pharmaceuticals, Inc. shares in Q3 2018, an estimated $142K.
  • PDT Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 5 quarters.
  • PDT Partners's Merrimack Pharmaceuticals, Inc. position peaked at $1.12M in Q3 2014.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on PDT Partners's 13F filing for Q3 2018, filed 14 Nov 2018.